‘Give me one week’s time’: Bharat Biotech chief on questions about Covaxin efficacy | Latest News India - Hindustan Times
close_game
close_game

‘Give me one week’s time’: Bharat Biotech chief on questions about Covaxin efficacy

Hindustan Times, New Delhi | Byhindustantimes.com | Edited by Shivani Kumar
Jan 04, 2021 08:56 PM IST

The government has cleared Bharat Biotech International Limited’s locally developed vaccine for “restricted use in emergency situation” triggering a debate among experts over the approval despite the shorter duration of human trials and relatively less data

Amid concerns over the relatively less amount of data on the efficacy and safety of Covaxin, developed by the Hyderabad-based Bharat Biotech, the company’s managing director Krishna Ella said on Monday that the company’s vaccine is safe and the company is conducting trials in more than 12 countries apart from India. “We are not a company without experience in vaccines. We have tremendous experience in vaccines,” ANI quoted Ella as saying.

A volunteer being vaccinated by a medic during the Bharat Biotech's 'Covaxin' human trial in Jaipur.(PTI)
A volunteer being vaccinated by a medic during the Bharat Biotech's 'Covaxin' human trial in Jaipur.(PTI)

“We are touching 123 countries. We are the only company that has got such extensive experience & extensive publication in review journals,” he also said.

Hindustan Times - your fastest source for breaking news! Read now.

“We are not just conducting clinical trials in India. We have done clinical trials more than 12 countries including the UK. We are doing clinical trials in Pakistan, Nepal, Bangladesh & other countries. We are not just an Indian company, we are truly a global company,” Ella also said.

Asked if the vaccine will be effective on new strain of the virus, Ella said, “Give me one week’s time, I will give you confirmed data.”

The government recently approved emergency authorisation use of Oxford-AstraZeneca’s Covishield. The government has also cleared Bharat Biotech International Limited’s locally-developed vaccine for “restricted use in emergency situation” triggering a debate among experts over the approval despite the shorter duration of human trials and relatively less data.

Meanwhile, Indian Council of Medical Research (ICMR) Director General Dr Balram Bhargava had said on Sunday that Covaxin is based on an inactivated whole virus, having potential to target mutated coronavirus strains including the UK variant, and it was a major reason for giving it a conditional nod.

Speaking on the controversy around the vaccine, Ella said, “Now that vaccine is being politicised, I want to state very clearly that none of my family members are associated with any political party.”

“Approval of Covaxin for emergency use is a giant leap for innovation and novel product development in India. It is a proud moment for the nation and a great milestone in India’s scientific capability, a kickstart to the innovation ecosystem in India,” Ella also said.

Unveiling Elections 2024: The Big Picture', a fresh segment in HT's talk show 'The Interview with Kumkum Chadha', where leaders across the political spectrum discuss the upcoming general elections. Watch now!

Get Current Updates on India News, Election 2024, Mukhtar Ansari Death News Live, Bihar Board 10th Result 2024 Live along with Latest News and Top Headlines from India and around the world.
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Friday, March 29, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On